RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Effectiveness of Letrozole Compared with Tamoxifen for Patients with Lobular Carcinoma in the BIG 1–98 Trial
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 12
IS 20
SP 10
OP 11
DO 10.1177/155989771220006
UL http://mdc.sagepub.com/content/12/20/10.abstract
AB Invasive lobular carcinoma (ILC) is the second most common breast cancer histologic subtype, accounting for 10% to 15% of all breast cancers, with classic lobular carcinoma being the most common variant. Aromatase inhibitors and tamoxifen are established therapies used for the adjuvant treatment of estrogen receptor-positive breast cancer, but the relative benefits in invasive ductal carcinomas (IDCs) and ILCs has not been extensively studied. This article presents an analysis of the Letrozole or Tamoxifen in Treating Postmenopausal Women with Breast Cancer [BIG 1–98] trial comparing the outcomes of patients with IDC and ILC treated with adjuvant letrozole or tamoxifen.